Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from...

The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of...

Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research...

Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed!...

If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD,...

Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers...

Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB...

Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus...

Immunophotonics has been featured in the March oncology issue of Nature Biopharma Dealmakers (www.nature.com/articles/d43747-021-00020-2 ). Nature selects only a handful...

A paper recently published in Cells has described how Immunophotonics' immune-stimulating drug IP-001 was shown to be effective against metastatic...